18 Results for "

Del19/T790M/C797S

" in MedChemExpress (MCE) Product Catalog:
Products (18)

18 Results for "Del19/T790M/C797S" in MCE Product Catalog:

Cat. No.: HY-129550
CAS No.: 2664214-60-0
Purity:  99.28%
Target:  

EGFR

Research Areas:  

Cancer

BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI-4020 also shows activity against EGFR wt (IC50=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties .
loading...
    loading...
Cat. No.: HY-156698
CAS No.: 2570251-68-0
Purity:  98.64%
Target:  

PROTACs EGFR

Research Areas:  

Cancer

HJM-561 is a selective and effective orally active EGFR PROTAC degrader. HJM-561 is able to overcome the triple EGFR mutations that are resistant to Osimertinib (HY-15772). HJM-561 exhibits potent degradation of EGFR Del19/T790M/C797S (DC50: 9.2 nM) and L858R/T790M/C797S (DC50: 5.8 nM), and has anti-tumor activity (pink: EGFR ligand (HY-12857); blue: CRBN ligand (HY-A0003); black: linker) .
loading...
    loading...
Cat. No.: HY-137191
CAS No.: 2923365-71-1
Purity:  99.61%
Target:  

EGFR

Research Areas:  

Cancer

CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities .
loading...
    loading...
Cat. No.: HY-163094
CAS No.: 3027135-04-9
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-95 (compound 5j) is an 2,4-diaminonicotinamide derivative. EGFR-IN-95 has potent inhibitory activity against EGFR del19/T790M/C797S and L858R/T790M/C797S .
loading...
    loading...
Cat. No.: HY-161126
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-98 (Compound 4c) is a EGFR inhibitor. The IC50 values of L858R/T790M/C797S and Del19/T790M/C797S are 0.277 μM and 0.089 μM, respectively. EGFR-IN 98 can be used in the study of tumors .
loading...
    loading...
Cat. No.: HY-143445
CAS No.: 2882851-77-4
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-48 is a potent and orally active EGFR inhibitor with IC50s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR d19/TM/CS, EGFR LR/TM/CS, EGFR WT, respectively. EGFR-IN-48 inhibits the proliferation of BaF3 EGFR del19/T790M/C797S and PC-9 EGFR del19/T790M/C797S cells with IC50s of 1.526, 66.7 nM, respectively .
loading...
    loading...
Cat. No.: HY-170497
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-140 (Compound 31) is the inhibitor for EGFR, that inhibits EGFR wildtype and EGFR L858R/T790M/C797S mutant with Ki of 0.95 nM and 2.1 nM, and inhibits EGFR del19/T790M/C797S in Ba/F3 with an IC50 of 56.9 nM. EGFR-IN-140 exhibits antitumor efficacy in mouse model .
loading...
    loading...
Cat. No.: HY-142517
CAS No.: 2749562-63-6
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-25 is a potent EGFR inhibitor with IC50s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively .
loading...
    loading...
Cat. No.: HY-168112
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-127 is an ATP-competitive EGFR inhibitor with IC50s of 136.3 nM and 161. 2 nM for EGFR del19 and EGFR del19/T790M/C797S, respectively. EGFR-IN-127 has the potential for the study of non-small-cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-157432
CAS No.: 3020681-05-1
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

EGFR-IN-97 (compound 6q) is a EGFR inhibitor. EGFR-IN-97 shows inhibitory activity against Ba/F3-EGFR L858R/T790M/C797S and Ba/F3-EGFR Del19/T790M/C797S cells, with IC50 values of 0.42 μM and 0.41 μM, respectively. EGFR-IN-97 can promote apoptosis of NCI-H1975-EGFR L858R/T790M/C797S cells at the concentration of 0.8 μM .
loading...
    loading...
Cat. No.: HY-156284
CAS No.: 2413029-40-8
Purity:  98.75%
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-89 (compound 13k) is a potent, fourth-generation EGFR mutation inhibitor with an IC50 of 10.1 nM against Del19/T790M/C797S mutations. EGFR-IN-89 shows higher selectivity over wild type .
loading...
    loading...
Cat. No.: HY-161319
CAS No.: 2758904-45-7
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-104 (Compound A23) is an effective inhibitor of EGFR, with IC50 values of 0.33 μM and 0.133 μM against EGFR L858R/T790M and EGFR Del19/T790M/C797S, respectively. EGFR-IN-104 exhibits anticancer activity both in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-155005
CAS No.: 2770009-06-6
Purity:  ≥97.0%
Target:  

EGFR

Research Areas:  

Cancer

EGFR mutant-IN-2 (Compound D51) is an EGFR mutant inhibitor. EGFR mutant-IN-2 inhibits the EGFR L858R/T790M/C797S mutant with an IC50 value of 14 nM. EGFR mutant-IN-2 inhibits the EGFR del19/T790M/C797S mutant with an IC50 value of 62 nM. EGFR mutant-IN-2 has favorable PK parameters, safety properties, in vivo stability, and antitumor activity .
loading...
    loading...
Cat. No.: HY-142680
CAS No.: 2747133-37-3
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC50 of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8) .
loading...
    loading...
Cat. No.: HY-149401
CAS No.: 2568086-81-5
Target:  

EGFR

Research Areas:  

Cancer

EGFR-IN-82 (Cmpound 8a) is a potent and orally active EGFR inhibitor with IC50 values of 0.09 and 0.06 nM for EGFR L858R/T790M/C797S and EGFR Del19/T790M/C797S, respectively. EGFR-IN-82 has no significant effect on EGFR WT. EGFR-IN-82 has anti-proliferative activity and inhibits tumor formation in nude mice. EGFR-IN-82 can be used in non-small cell lung cancer research .
loading...
    loading...
Cat. No.: HY-161785
CAS No.: 3035639-05-2
Target:  

Apoptosis EGFR

Research Areas:  

Cancer

EGFR-IN-117 (Compound 8h) exhibits inhibitory activity against EGFR mutation, targets the tumor environment, and induces apoptosis of cancer cells. EGFR-IN-117 inhibits proliferations of H1975, PC-9, and EGFR mutant cells BaF3-EGFR L858R/T790M/C797S and BaF3– C797S/Del19/T790M, with IC50 of 13 nM, 19 nM, 1.2 nM and 1.3 nM, respectively. EGFR-IN-117 exhibits antitumor efficacy in mouse models .
loading...
    loading...
Cat. No.: HY-170928
CAS No.: 2756978-82-0
DA-0157 is the orally active inhibitor for EGFR and ALK that overcomes drug-resistant mutations of EGFR C797S and ALK in NSCLC) cells. DA-0157 inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50 = 6.9 nM), Ba/F3-EGFR WT (IC50 = 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50 = 5.5 nM), and Ba/F3-EML4-ALK (IC50 = 7.4 nM). DA-0157 inhibits CYP2D6 with IC50 of 5.26 μM. DA-0157 exhibits antitumor efficacy in mouse models .
loading...
    loading...
Cat. No.: HY-183277
CAS No.: 3088042-00-3
Target:  

EGFR p38 MAPK Akt Apoptosis

Research Areas:  

Cancer

EGFR-IN-209 (Compound 6g) is an orally active, selective EGFR Del19/T790M/C797S inhibitor with an IC50 of 0.056 μM. EGFR-IN-209 blocks the phosphorylation of EGFR and its downstream effector molecules (pMAPK, pAKT). EGFR-IN-209 induces Apoptosis. EGFR-IN-209 exhibits antitumor activity against Osimertinib (HY-15772)-resistant non-small cell lung cancer. EGFR-IN-209 can be used in research related to non-small cell lung cancer .
loading...
    loading...
  • 1